



Cytocentrics gaining traction in San Antonio

Roughly seven months after moving its headquarters from Rostock, Germany, to San Antonio, Cytocentrics Inc. is already making noise in its new home via a new deal.

Cytocentrics has entered into a business collaboration with Cologne, Germany-based Axiogenesis. Under the deal, Cytocentrics will become the exclusive U.S. distributor of Axiogenesis' novel cardiomyocyte cell lines and an American portal for the company's other stem cell products.

As CEO James Garvin teased in June, Cytocentrics is positioning San Antonio for greater opportunities in the drug development industry. The company has combined bioscience, nano science, microchip development, algorithms and engineering to develop and manufacture medical devices that support ion channel research and new approaches to disease analysis and personalized pharmacology.

Axiogenesis' proprietary technology enables the reprogramming of human skin or blood cells into embryonic-like stem cells.

Garvin said Axiogenesis' unique innovations, coupled with his company's capabilities, will help accelerate and improve the process of selecting drug candidates and advance personalized medicine.

He said the deal with Axiogenesis will open more eyes.

"It continues to show the respect the market has for the technology and broadens our product set and footprint considerably," Garvin said.

In addition, Garvin said the collaboration with Axiogenesis could lead to the German company establishing a larger presence in San Antonio.

"That certainly is something we are discussing," he said.

Source: http://www.bizjournals.com/sanantonio/print-edition/2016/01/15/cytocentrics-gaining-traction-in-san-antonio.html?ana=e_ph_prem&u=xwaEjzicoSEklpSFGfyN5CB/zV&t=1456991734

January 15th 2016